Vemurafenib in melanoma - PubMed (original) (raw)

Review

Vemurafenib in melanoma

Heather M Shaw et al. Expert Rev Anticancer Ther. 2013 May.

Abstract

The incidence of malignant melanoma is increasing annually. Early stages can be cured with surgical intervention but metastatic disease has generally had a dismal prognosis with few effective interventions. A half of all melanomas possess a BRAF mutation, which can be targeted by specific inhibitors. Vemurafenib is an orally active, purposely designed mutant BRAF inhibitor, which has recently been shown to have a survival benefit measured in months in metastatic patients. In this article, the authors discuss the scientific rationale, drug development process and clinical trials that have led to vemurafenib becoming the first BRAF inhibitor approved for the treatment of patients with mutant BRAF metastatic melanoma.

PubMed Disclaimer

Cited by

The current role and evolution of X-ray crystallography in drug discovery and development.
Bijak V, Szczygiel M, Lenkiewicz J, Gucwa M, Cooper DR, Murzyn K, Minor W. Bijak V, et al. Expert Opin Drug Discov. 2023 Jul-Dec;18(11):1221-1230. doi: 10.1080/17460441.2023.2246881. Epub 2023 Aug 17. Expert Opin Drug Discov. 2023. PMID: 37592849 Free PMC article. Review.
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
Bhatia S, Pavlick AC, Boasberg P, Thompson JA, Mulligan G, Pickard MD, Faessel H, Dezube BJ, Hamid O. Bhatia S, et al. Invest New Drugs. 2016 Aug;34(4):439-49. doi: 10.1007/s10637-016-0348-5. Epub 2016 Apr 8. Invest New Drugs. 2016. PMID: 27056178 Free PMC article. Clinical Trial.
The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial.
Rutkowski P, Kozak K, Mackiewicz J, Krzemieniecki K, Nawrocki S, Wasilewska-Teśluk E, Kwinta Ł, Wysocki P, Koseła-Paterczyk H, Świtaj T. Rutkowski P, et al. Contemp Oncol (Pozn). 2015;19(4):280-3. doi: 10.5114/wo.2015.54082. Epub 2015 Sep 28. Contemp Oncol (Pozn). 2015. PMID: 26557775 Free PMC article.
Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.
Malemud CJ, Blumenthal DE. Malemud CJ, et al. World J Orthop. 2014 Sep 18;5(4):496-503. doi: 10.5312/wjo.v5.i4.496. eCollection 2014 Sep 18. World J Orthop. 2014. PMID: 25232525 Free PMC article. Review.
Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.
Etnyre D, Stone AL, Fong JT, Jacobs RJ, Uppada SB, Botting GM, Rajanna S, Moravec DN, Shambannagari MR, Crees Z, Girard J, Bertram C, Puri N. Etnyre D, et al. Cancer Biol Ther. 2014 Sep;15(9):1129-41. doi: 10.4161/cbt.29451. Epub 2014 Jun 11. Cancer Biol Ther. 2014. PMID: 24914950 Free PMC article.

Vemurafenib in melanoma - PubMed (original) (raw)